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C–X–C-chemokine ligand 13 (CXCL13), the ligand for C–X–C chemokine receptor type 5 
(CXCR5), is a major regulator of B-cell trafficking and plays an integral role in age-depen-
dent clearance of hepatitis B virus (HBV) in the mouse model. However, the expression 
and function of CXCL13 in patients with chronic hepatitis B (CHB) remain unknown. 
By use of liver cell subpopulations isolated from CHB patients, we found that CXCL13 
mRNA was abundantly expressed in Kupffer cells (KCs), but not in primary hepatocytes, 
liver sinusoidal endothelial cells, and hepatic stellate cells. Interestingly, KC isolated from 
HBV-positive liver had much higher level of CXCL13 expression than non-HBV-infected 
controls. And its expression was induced by toll-like receptor 3 ligand poly I:C stimula-
tion. Moreover, intense expression of CXCL13 protein and accumulation of CD4+ T and 
B cells were evident in follicular-like structures in the liver tissue of CHB patients, which 
indicated its chemotactic effect on CXCR5+ CD4+ cells and B cells. Consistently, the 
levels of serum CXCL13 were significantly higher in the CHB patients than in healthy 
controls. Furthermore, CXCL13 concentration was increased in the complete response 
(CR) group during weeks 0–12 and did not change significantly during the course of 
telbivudine treatment, compared with the patients who didn’t achieve CR. In conclusion, 
the HBV-related increase of CXCL13 production in KC and serum CXCL13 level during 
telbivudine treatment might be associated with immune control of chronic HBV infection.
Keywords: hepatitis B virus, chronic hepatitis B, cXcl13, Kupffer cell, hepatitis B virus e antigen seroconversion
Abbreviations: ALT, alanine aminotransferase; CHB, chronic hepatitis B; CR, complete response; CXCL13, C–X–C-chemokine 
ligand 13; CXCR5, C–X–C chemokine receptor type 5; ELISA, enzyme-linked immunosorbent assay; FDC, follicular dendritic 
cell; GCs, germinal centers; HBeAg, hepatitis B virus e antigen; HBV, hepatitis B virus; HC, healthy control; HCV, hepatitis C 
virus; HSC, hepatic stellate cell; IA, immune activation; IC, inactive carrier; IFN, interferon; IL-21, interleukin-21; IT, immune 
tolerance; KC, Kupffer cell; LSEC, liver sinusoidal endothelial cell; NCR, non-complete response; NPCs, non-parenchymal cells; 
PBMC, peripheral blood mononuclear cell; PHH, primary human hepatocyte; TBIL, total bilirubin; TFH, follicular T helper 
cells; TLR, toll-like receptor.
TaBle 1 | clinical characteristics of the subjects.
group ia iT ic hc
No. of patients 20 10 15 12
Gender (M/F) 14/6 6/4 5/10 8/4
Age (years) 28.00 (21.00–41.80) 26.50 (3.80–34.70) 36.00 (22.60–54.40) 24.00 (21.30–34.40)
Hepatitis B virus (HBV) DNA (log10 copies/ml) 8.40 (5.94–9.39) 7.70 (5.55–8.70) 0.00a (0.00–3.94) ND
ALT (U/l) 145.00 (70.60–295.30) 22.00 (16.10–40.90) 18.00 (10.60–33.40) 15.00 (12.00–27.70)
AST (U/l) 90.50 (48.10–225.40) 24.50 (19.30–34.50) 25.00 (16.40–35.00) 22.00 (12.00–31.20)
HBsAg positive 20 10 12 0
Anti-HBs positive 0 0 1 6
Hepatitis B virus e antigen positive 20 5 5 0
Anti-Hbe positive 0 5 7 0
Anti-HBc positive 20 10 15 0
CXCL13 (pg/ml) 67.18 (46.77–180.51) 42.30 (23.92–85.69) 31.93 (17.46–98.42) 32.33 (13.69–49.90)
Data were shown as median and 10–90% percentile.
a11 IC had undetectable HBV DNA.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; HC, healthy control; IA, immune activation; IC, inactive carrier; IT, immune tolerance; ND, not determined.
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inTrODUcTiOn
Hepatitis B virus (HBV) is a non-cytopathic hepadnavirus that 
chronically infects approximate 240 million people. Every year, 
HBV-associated end-stage liver disease results in about 1 million 
patient deaths (1). It is well known that the chance of clearing 
HBV infection is age-dependent and relies on the host immune 
system. Over 95% of adult patients who acquired HBV infections 
have spontaneous clearance, but 90% of neonates and 30% of 
children 1- to 5-year olds who acquired HBV infections fail to 
resolve the infection and develop chronic hepatitis B (CHB) (2, 
3). Generally, the natural history of chronic HBV infection can be 
divided into different phases, including immune tolerance (IT), 
immune activation (IA), inactive carrier (IC), and reactivation (4, 
5). During the IA phase, the host immune system, including both 
innate and adaptive immune responses, were activated to clear the 
virus from hepatocytes. A strong, diverse, and functional adap-
tive immune response is considered essential for HBV clearance. 
However, it has been clearly shown that deletion or exhaustion of 
adaptive immunity leads to HBV persistence in hepatocytes (6).
Liver inflammation accompanied by elevated levels of serum 
alanine aminotransferase (ALT) in CHB patients are usually 
observed and result from immune-mediated destruction of 
hepatic cells. Within the inflamed liver, there is an accumulation 
of lymphoid and myeloid cells, including T and B cells (7). These 
immune cells play critical roles in the clearance of HBV-infected 
hepatocytes but also are involved in immune-mediated liver dam-
age and inflammation (8). Accumulating evidence indicates that 
certain chemokines in the liver are necessary for providing the 
appropriate environment for activation and expansion of naïve 
lymphocytes in response to hepatitis virus infection (9). Using 
a mouse model of HBV infection, it was found that chemokine 
C–X–C-chemokine ligand 13 (CXCL13), which is involved in 
hepatic B-lymphocyte trafficking and lymphoid architecture and 
development, is expressed in an age-dependent manner in mouse 
hepatic macrophages and plays an integral role in facilitating an 
effective immune response against HBV (10).
CXCL13 is a member of CXC subtype of chemokine super-
family and is also known as a B  cell—attracting chemokine 1 
or B-lymphocyte chemoattractant (11). By acting through its 
cognate receptor C–X–C chemokine receptor type 5 (CXCR5), 
CXCL13 is chemotactic for mature B cells and T follicular helper 
(Tfh) cells (12). Importantly, CXCL13 facilitates the co-migration 
of B cells and Tfh cells into B cell follicles and germinal centers 
(GCs), where high-affinity antibody-secreting memory B and 
plasma cells are generated (13). Aberrant circulating CXCL13 
levels have been implicated in the pathogenesis of many chronic 
inflammatory diseases and correlated with clinical outcomes, 
including various infections and autoimmune disorders associ-
ated with dysregulated humoral responses (14–16).
Previous work from our group suggested that circulating Tfh 
cells might have a significant role in facilitating hepatitis B virus e 
antigen (HBeAg) seroconversion through interleukin-21 (IL-21) 
secretion in patients with chronic HBV infection (17). However, 
the association of CXCL13 expression with the pathogenesis of 
CHB and clinical outcome of antiviral therapy remains unclear. 
The present study was designed to examine CXCL13 expression 
and regulation in subpopulations of hepatic cells, as well as in 
the serum at different phases of CHB patients. In addition, we 
performed an in-depth prospective analysis of the kinetics of 
serum CXCL13 expression of CHB patients being treated with 
telbivudine with different clinical outcomes.
MaTerials anD MeThODs
study subjects
Blood samples were obtained from 45 patients with chronic HBV 
infection who were recruited at Nanfang Hospital (Guangzhou, 
China) for a cross-sectional study. They were classified into three 
groups according to guidelines from the European Association 
for the Study of Liver Diseases: IA (n = 20); IT (n = 10), and IC 
(n = 15) (18). A total of 12 healthy controls (HCs) were enrolled 
for comparison. Demographic, biochemical, and virological 
features of the participants were listed in Table 1.
Fifty-five HBeAg-positive CHB subjects from Nanfang 
Hospital who had participated in two prospective clinical trials 
of telbivudine (600 mg/day, clinical trial numbers: NCT00962533 
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and CLDT600ACN07T) were also studied. According to treat-
ment response at week 52, the participants were classified into 
a complete response (CR) group or a non-complete response 
(NCR) group (18). Subjects in the CR group had undergone ALT 
normalization and HBeAg seroconversion, and had achieved a 
serum HBV-DNA level of < 300 copies/ml by week 52; those in 
the NCR group had either a serum HBV-DNA level >300 copies/
ml or were positive for HBeAg at week 52. All patients provided 
written documentation of informed consent. The study conforms 
to the ethical guidelines of the 1975 Declaration of Helsinki and 
was approved by the Ethical Committee of Nanfang Hospital.
serological assays and hBV-Dna assays
The presence of HBV surface antigen, HBeAg, anti-HBs, anti-
HBe, and anti-HBc was determined using ARCHITECT i2000SR 
system (Abbott Ireland Diagnostics Division, Sligo, Ireland) (19). 
HBV DNA was measured using the COBAS TaqMan HBV Test 
(Roche Molecular Diagnostics, Pleasanton, CA, USA) (17), which 
has a detection limit of 12 IU/ml (1 IU/ml = 5.82 copies/ml).
enzyme-linked immunosorbent assay 
(elisa)
The concentration of CXCL13 was quantitated in duplicate wells 
using a commercial human CXCL13 ELISA kit (R&D Systems, 
Minneapolis, MN, USA) in accordance with the manufacturer’s 
instructions.
PBMcs isolation and Macrophage 
Differentiation
Peripheral blood mononuclear cells were separated on Ficoll-
Histopaque (BD Biosciences, Shanghai, China) density gradients 
and routinely cryopreserved as previously described (17). The 
monocytes were isolated from PBMCs by adherence to plates 
coated with collagen-I (BD Biosciences, USA) at 37°C in RPMI 
1640 containing 10% FBS (20). After incubation, the cells were 
washed by PBS for 5 min and then gently vibrated on a culture 
plate. The monocytes were then cultured for up to 9 days in the 
presence 10 ng/ml of GM-CSF (PerproTech, Rocky Hill, NJ, USA) 
in RPMI 1640 containing 10% FBS. This protocol resulted in 
more than 90% purity of the macrophages, as determined by flow 
cytometry analysis (FACS) using anti-CD14 APC-conjugated 
monoclonal antibody (BD Biosciences, USA). The differentiated 
macrophages were then stimulated for 6 h with 5 μg/ml of LPS or 
poly I:C (InvivoGen, San Diego, CA, USA).
Primary human hepatocytes (Phhs) and 
non-Parenchymal cells isolation and 
incubation
Liver specimens (25–100  g) were obtained from fresh tumor 
resections or liver transplantation donors (HBV-positive, n = 6; 
HBV-negative, n  =  6, patients’ information is in Table S1 in 
Supplementary Material). PHHs and non-parenchymal liver 
cells, including Kupffer cells (KCs), liver sinusoidal endothelial 
cells (LSECs), and hepatic stellate cells (HSCs), were prepared 
from a single human liver specimen according to a modified 
two-step perfusion technique, as described by our group recently 
(21). The study conforms to the ethical guidelines of the 1975 
Declaration of Helsinki and was approved by the Institutional 
Review Board (ethics committee) of the medical faculty at the 
University of Duisburg-Essen. PHHs were seeded into collagen-I 
(BD Biosciences, USA) coated plates at a density of 1.25 to 
2.5 × 105 viable cells per cm2 by using DMEM/Ham’s F-12 medium 
(Biochrome, Berlin, Germany) supplemented with 10% FBS. KCs 
were seeded onto plastic culture plates at a density of 4 to 6 × 105 
cells per cm2 using DMEM supplemented with 10% FBS. LSECs 
were cultured in coated plates with Endothelial Growth Medium 
2 (PromoCell, Heidelberg, Germany) containing provided sup-
plements. HSCs were seeded into an uncoated plastic culture 
flask with Stellate Cell Medium (ScienCell, Carlsbad, CA, USA) 
supplemented with supplied 10% FBS, 1% stellate cell growth sup-
plement. The purities of PHH (95.5 ± 1.7%), KC (94.5 ± 1.2%), 
LSEC (97.8 ± 1.1%), and HSC (97.1 ± 1.5%) could be reached as 
determined by immunofluorescence staining with specific mark-
ers (21). These cells were stimulated using the Human toll-like 
receptor (TLR) 1–9 Agonist Kit (Invivogen, Toulouse, France) at 
recommended concentrations for 6 h. Cells were then collected 
for RNA extraction and CXCL13 gene expression analysis by 
real-time RT-PCR was performed using commercially available 
primer set (Qiagen, Hilden, Germany) and normalized to β-actin 
as previously described (22).
rna extraction, reverse Transcription, 
and Quantitative real-time Pcr
Total cellular RNA was isolated and purified from PBMCs, 
stimulated macrophages or hepatic cells using the RNeasy Mini 
Kit (Qiagen, Hong Kong, China) according to the manufacturer’s 
instructions. The cDNA synthesis was performed with 200 ng 
total RNA using the Transcriptor First Strand cDNA Synthesis 
Kit (Roche, Mannheim, Germany). The expression of CXCL13 
genes was determined by real-time RT-PCR, which was per-
formed using the SYBR Green I Master Kit (Roche, Switzerland) 
on a LightCycler 480 (Roche Diagnostics, Switzerland), as 
described previously (23). The expression levels of each gene 
are presented as values normalized against 106 copies of β-actin 
transcripts.
immunohistochemistry
Immunohistochemistry was performed on formalin-fixed and 
paraffin-embedded 4-μm sections of liver tissue. Sections were 
incubated overnight at 4°C with appropriate concentrations of 
primary antibodies, including rabbit anti-CD4, mouse anti-
CD19, rabbit anti-CD38, mouse anti-CD68, and mouse anti-
CXCR5 (Abcam, Cambridge, MA, USA) and goat anti-CXCL13 
(R&D System, USA), and then incubated with the Dako Chemate 
Envision Kit (Dako, Glostrup, Denmark). The reaction was visu-
alized by CheMate™ DAB plus chromogen (Dako, Denmark). 
The staining was captured by light microscopy using high-power 
microscopic fields (400×).
chemotaxis assay
Chemotaxis was assessed in a two-chamber transwell cell 
migration system (5-μm pores, Corning, Shanghai, China) (24). 
FigUre 1 | cXcl13 expression in subpopulation of liver cells and its regulation by toll-like receptor (Tlr) ligands. (a) Comparison of CXCL13 mRNA 
expression in Kupffer cell (KC), hepatic stellate cell (HSC), liver sinusoidal endothelial cell (LSEC), and primary human hepatocyte (PHH). Different subpopulation of 
liver cells were isolated from non-hepatitis B virus-infected livers. The total RNA of these cells was extracted and the expression of CXCL13 mRNA was determined 
by real-time RT-PCR. (B) Comparison of CXCL13 mRNA expression in KC after stimulation with TLR1–9 ligands. Isolated KC were stimulated with different TLR1–9 
ligands for 6 h and then harvested for RNA extraction. CXCL13 mRNA expression was determined by real-time RT-PCR. The stimulus and concentration used as 
below: TLR1/2 agonist: Pam3CSK4 (4 μg/ml), TLR2 agonist: HKLM (108 cells/ml), TLR3 agonist: poly I:C (50 μg/ml), TLR4 agonist: LPS (30 μg/ml), TLR5 agonist: 
FLA (2 μg/ml), TLR6/2 agonist: FSL1 (1 μg/ml), TLR7 agonist: imiquimod (20 μg/ml), TLR8 agonist: ssRNA40 (10 μg/ml), TLR9 agonist: CpG (31.8 μg/ml). Data are 
representative with mean ± SEM, and determined by Mann–Whitney U test.
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PBMCs from CHB patients (1 × 106) were purified as described 
above and were seeded in the upper well, and different concentra-
tions of recombinant human CXCL13 (rh-CXCL13, PerproTech) 
or RPMI 1640 as controls were added to the bottom well as the 
chemoattractant. The cells were cultured for 2–6 h at 37°C and 
then collected and stained with CD19-APC, CD4-PE-Cy7, and 
CXCR5-PerCP-Cy5.5 (BioLegend, San Diego, CA, USA) The 
percentage of migrating cells was analyzed and calculated by a 
BD FACSCanto II flow cytometer.
statistical analysis
Continuous data were expressed as medians (minimum–maxi-
mum). The Mann–Whitney U test, Wilcoxon’s signed-ranks test, 
and the chi-squared test were used for two-group comparisons. 
The Kruskal–Wallis H test was used when comparing more than 
three groups. Repeated measures analysis was used to compare 
changes in CXCL13 expression during treatment. The paired 
Student’s t-test was used to compare individual values at different 
times. Receiver-operating characteristic (ROC) curves were con-
structed to predict a CR to LdT treatment. All statistical analyses 
were based on two-tailed hypothesis tests with a significance level 
of p < 0.05.
resUlTs
cXcl13 expression in liver cells is 
regulated by Tlr agonists stimulation
Previous studies in mouse model suggested that CXCL13 was 
predominantly expressed in liver macrophages (10). However, 
the expression of CXCL13 in human liver cells remains unknown. 
PHH and non-parenchymal liver cells composed of KC, LSEC, 
and HSC were isolated from fresh human liver specimens 
obtained from HBV-negative tumor resections of patients 
(n =  6). The CXCL13 mRNA expression in different liver cell 
subpopulations was examined by real-time RT-PCR. The basal 
expression of CXCL13 in KC, HSC, LSEC, and PHH isolated 
from non-HBV-infected livers was very low and had no signifi-
cant difference (Figure 1A). Further, we investigated if CXCL13 
expression was regulated by pathogen-associated molecular 
patterns; to do this we used various TLR1–9 agonists to stimulate 
the KC isolated from liver resections without HBV infection. We 
found that the CXCL13 mRNA expression could be induced by 
TLR3 agonist poly I:C for about 7.2-fold (p = 0.03), whereas other 
TLRs agonists had no significant effect (Figure 1B). As positive 
controls, interferon (IFN)-β induction was observed in poly I:C 
stimulation and all TLR ligands, except TLR9 ligand CPG, were 
able to induce IL-6 expression at different levels in KC (Figures 
S1A,B in Supplementary Material). Consistently, by using in vitro 
differentiated macrophages from monocytes (Figure S2A in 
Supplementary Material), poly I:C were able to induce CXCL13 
expression at mRNA (Figure S2B in Supplementary Material) and 
protein levels (Figure S2C in Supplementary Material).
Kc isolated from hBV-Positive liver 
Tissues express higher levels of  
cXcl13 in response to Tlr3 agonist 
Poly i:c compared to Kc with  
hBV-negative Origin
To assess whether HBV infection could influence CXCL13 
expression, we compared the basal and TLR3 agonist-induced 
expression of CXCL13 in liver cell subpopulations between 
HBV-positive and HBV-negative patients (n = 6 for each group). 
Interestingly, the KC isolated from HBV-positive patients 
had much higher level of CXCL13 expression than non-HBV 
patients (about 45-fold, p <  0.001, Figure  2A). Upon poly I:C 
stimulation, the induced CXCL13 expression in KC isolated 
FigUre 2 | Toll-like receptor (Tlr) 3 agonist-induced expression of cXcl13 in liver cells from hepatitis B virus (hBV)-positive and non-hBV-infected 
patients. Comparison of the basal and TLR3 agonist-induced expression of CXCL13 in Kupffer cell (KC) (a), hepatic stellate cell (HSC) (B), liver sinusoidal 
endothelial cell (LSEC) (c), and primary human hepatocyte (PHH) (D). Different subpopulation of liver cells were isolated from either Non-HBV or HBV-positive 
subjects and stimulated with or without TLR3 agonist for 6 h. Total RNA was extracted and then the CXCL13 mRNA expression to β-actin were determined by 
real-time RT-PCR. Data are representative with mean ± SEM, and determined by Mann–Whitney U test and Wilcoxon’s signed-ranks test.
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from HBV-positive patients was also markedly higher than in 
non-HBV patients (Figure  2A, p =  0.004). However, the basal 
expression of CXCL13 in other cells including HSC (Figure 2B), 
LSEC (Figure 2C), and PHH (Figure 2D) had no significant dif-
ference among these two groups. Moreover, poly I:C stimulation 
had very weak effect on inducing CXCL13 expression in these 
cells, except PHH (p = 0.005).
serum cXcl13 concentrations is 
increased in the immune-activation 
Phase of chronic hBV infection and 
negatively correlated with hBV-Dna 
levels
To elucidate whether serum CXCL13 levels in patients could 
also be affected by HBV infection, we examined the concentra-
tion of CXCL13 by ELISA in CHB patients. We saw that serum 
CXCL13 was significantly higher in CHB patients than in HCs 
(Figure 3A, p = 0.003). The CHB patients were further divided 
into three groups (IA, IT, and IC) depending on ALT levels and 
viral parameters. The median serum CXCL13 concentrations in 
the IA groups were higher compared with the IT, IC, and HC 
groups, and there was no significant difference among the IT, IC, 
and HC groups (Figure 3A). Serum CXCL13 concentrations were 
negatively and weakly correlated with serum HBV-DNA levels in 
CHB patients (Figure 3B, r2 = 0.077, p = 0.016) but were uncor-
related with ALT levels (Figure 3C, p = 0.259). Consistent with 
previous data in human infant and adult samples (10), there was a 
weak positive correlation between serum CXCL13 concentration 
and age (Figure 3D, r2 = 0.051, p = 0.051).
Dynamic change of serum cXcl13 
concentrations under Telbivudine Therapy 
correlates with Treatment Outcome
To assess changes of serum CXCL13 concentrations in HBV-
infected patients during nucleoside analog therapy, we studied 
55 HBeAg-positive CHB patients who received 52 weeks of tel-
bivudine treatment. During this antiviral treatment, the serum 
CXCL13 concentrations in all patients gradually decreased 
from 0 to 52 weeks of therapy, while the serum CXCL13 con-
centrations at baseline and 12  weeks were higher than at 24 
and 52 weeks (Figure 4A). These patients were further divided 
into CR and NCR group as described in Section “Materials and 
Methods” (19). The features (age and sex, as well as serum ALT, 
AST, TBIL, HBV-DNA, and CXCL13 levels) of the CR group 
and NCR group from baseline to 52 weeks during therapy were 
compared (Table 2). Mean ALT levels of the CR group decreased 
FigUre 3 | cXcl13 expression in serum samples from chronic hepatitis B (chB) patients and its correlation with viral parameters. (a) Comparison of 
serum CXCL13 concentration in healthy control (HC) and CHB patients with chronic hepatitis B virus (HBV) infection [divided into immune activation (IA), IT, and IC 
groups]. Serum CXCL13 concentrations were measured by specific enzyme-linked immunosorbent assay kit. Data are representative with median, and determined 
by Mann–Whitney U test. (B) The correlation between serum CXCL13 concentrations and HBV DNA (log10 copies/ml) in IA patients, including the baseline of CHB 
patients received telbivudine therapy. (c) The correlation between serum CXCL13 concentrations and alanine aminotransferase (ALT) levels in IA patients. (D) The 
correlation between serum CXCL13 concentrations and the age in IA patients.
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to normal at week 12, and were much lower than in the NCR 
group at 12  weeks (p =  0.042). Serum HBV-DNA levels were 
lower in CR group than NCR group at 12, 24, and 52  weeks 
(p <  0.005). Furthermore, the serum CXCL13 was higher in 
the CR than the NCR group at 12 and 52 weeks (Figure 4B). 
Repeated measures analysis showed that serum CXCL13 con-
centration decreased in the NCR group during therapy but in the 
CR group it remained largely unchanged (Figure 4C). Finally, 
ROC curves were generated to assess the usefulness of 12-week 
CXCL13 concentrations, 0-week log10 HBV DNA− 12-week log10 
HBV DNA, and combination factors between them to predict 
a CR at 52  weeks (Figure  4D). The combination factor was 
calculated from logistic regression analysis between CXCL13 
concentrations and value of 0-week log10 HBV DNA− 12-week 
log10 HBV DNA. The optimal cut-off value for the 12-week 
CXCL13 concentration was 58.1  pg/ml. This indicated that 
sensitivity for detection of a CR was 42.9% with a specificity of 
85.3%. The optimal cut-off value for log10 HBV DNA was 5.2, 
which provided sensitivity for detection of a CR of 47.6% and a 
specificity of 91.2%. The optimal cut-off value for combination 
factors was 0.41. This provided detection sensitivity for a CR of 
76.2% and a specificity of 88.2%.
cXcl13 is involved in the Formation of 
ectopic gc in the liver Tissue of chB 
Patients
CXCL13 is known to dictate homing and motility of CXCR5+ 
lymphocytes, we examined the chemotaxis using CHB patient 
PBMCs by Transwell test (Figure 5A). With a concentration of 
1 μg/ml CXCL13 in the bottom, the cell counting of CXCR5+ 
lymphocytes that moved through the membrane increased 
significantly (Figure  5B). In addition, with the response time 
extended, an increasing number of CXCR5+ lymphocytes moved 
through the Transwell filter membrane, and univariate post hoc 
analysis indicated that CXCL13 chemotaxis appeared to be time 
dependent (Figure 5C).
In order to verify the co-localization of CXCL13 and CXCR5+ 
in cells, we performed immunohistochemical staining of serial 
sections from liver samples. The staining of CXCL13 was very 
low in the liver tissue of most CHB patients and all HC group 
patients. However, there was positive CXCL13 staining in ectopic 
GCs of CHB liver biopsy samples (Figure 6A). Interestingly, co-
localization of CXCL13 with CD68+ KCs could be seen in serial 
sections of the liver biopsies, which reflected an accumulation of 
FigUre 4 | longitudinal analysis of serum cXcl13 concentrations of chronic hepatitis B (chB) patients during telbivudine therapy. (a) Comparison of 
serum CXCL13 concentrations at baseline and at 12, 24, and 52 weeks after starting telbivudine therapy in all 55 hepatitis B virus e antigen-positive CHB patients. 
Data are representative with median, and determined by Mann–Whitney U test and Kruskal–Wallis H test. (B) Comparison of serum CXCL13 concentrations 
between complete response (CR) group and non-complete response (NCR) group at indicated time points. Data are representative with median, and determined by 
Mann–Whitney U test. (c) Repeated measures analysis of temporal dynamics of serum CXCL13 concentrations between CR group and NCR group at indicated 
time points. The paired Student’s t-test was used to compare individual values at different time points. (D) Receiver-operating characteristic (ROC) curves for 
prediction of CR after telbivudine therapy, including CXCL13 concentrations at week 12, log10 HBV DNA copies/ml of week 0 − week 12, and combination factors 
above.
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CXCR5+ CD4+ T cells, and CXCR5+CD19+ B cells in the ectopic 
GCs in CHB liver, and CD38+ cells accumulation surrounding 
the GCs (Figure  6B). These results suggest that CXCL13 was 
involved in the recruitment of CXCR5+ lymphocytes in the liver 
of CHB patients.
DiscUssiOn
In the present study, we examined the CXCL13 expression in dif-
ferent hepatic cells from CHB patients and found that CXCL13 
was highly expressed and induced by poly I:C stimulation in KC 
isolated from HBV-positive livers. Serum CXCL13 concentrations 
were consistently increased and negatively correlated with HBV-
DNA titers in immune-active CHB patients. Moreover, serum 
CXCL13 in CR patients was found to be significantly higher than 
in NCR patients beginning at 12 weeks of telbivudine treatment. 
This suggests a role for CXCL13 in predicting CR to antiviral 
therapy. The findings presented here provide further evidence to 
support CXCL13 as an important chemokine for immune control 
of HBV infection.
Chronic hepatitis B has been associated with chronic inflam-
mation mediated by immune cells, inflammatory cytokines, 
and chemokines (25). KCs are tissue-resident macrophages 
and are crucial cellular components of the intrahepatic innate 
immune system (26). Based on their localization, KCs are 
likely to interact with HBV. However, the role of KCs in induc-
ing immunity toward HBV is poorly understood (27). As we 
found with results from the HBV transgenic mice model, we 
confirmed that KCs from HBV-positive patients had higher 
level of CXCL13 expression. It is likely that HBV infection could 
TaBle 2 | Univariate analysis of routine markers possibly associated with hepatitis B virus e antigen seroconversion.
Variable TW complete response non-complete response χ2/t/Z p
No. of patients 21 34
Male (n, %)a 16 (76.2%) 28 (82.6%) 0.308 0.579
Age (years)b 27.00 (19.40–37.40) 28.00 (21.00–35.50) 0.110 0.913
ALT (U/l)b 0 174.00 (85.40–313.80) 115.50 (59.00–301.00) 1.841 0.071
12 28.00 (16.00–85.20) 50.00 (17.00–125.00) −2.088 0.042#
24 20.00 (12.40–28.80) 24.00 (13.50–63.00) −1.944 0.057
52 20.00 (12.20–35.00) 19.00 (11.50–42.00) −0.654 0.516
AST (U/l)b 0 105.00 (48.20–152.40) 86.00 (43.00–179.50) 0.695 0.490
12 31.00 (21.40–46.60) 38.00 (25.00–58.50) −1.803 0.077
24 25.00 (19.20–36.40) 26.00 (20.50–39.50) −1.324 0.191
52 30.00 (18.60–76.40) 30.50 (19.50–51.50) 1.218 0.229
TBIL (μmol/ml)b 0 15.20 (8.72–25.26) 13.60 (8.45–22.10) 0.471 0.640
12 11.30 (7.34–19.56) 13.20 (8.65–20.60) −1.298 0.200
24 12.10 (6.56–24.74) 13.35 (7.60–23.65) −1.174 0.246
52 13.00 (7.94–21.94) 12.10 (8.15–22.45) −0.369 0.714
Hepatitis B virus DNA (log10 
copies/ml)b
0 8.37 (6.49–9.41) 8.66 (7.11–9.53) −0.699 0.487
12 3.27 (2.14–4.70) 4.14 (3.11–5.55) −4.430 0.000#
24 2.34 (1.82–3.73) 3.36 (2.29–5.35) −4.212 0.000#
52 1.84 (1.81–2.46) 2.19 (1.81–5.97) −3.306 0.002#
CXCL13 (pg/ml)c 0 48.77 (27.87–89.09) 45.51 (26.67–70.97) −1.109 0.268
12 51.42 (27.19–203.65) 41.80 (24.55–63.96) −2.105 0.035#
24 40.90 (19.14–374.20) 35.61 (23.37–60.83) −1.516 0.130
52 47.88 (24.10–160.68) 36.77 (15.71–49.50) −2.876 0.004#




TW, treatment week; IL, interleukin; TBIL, total bilirubin; ULN, upper limit of normal.
#p < 0.05.
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stimulate CXCL13 expression, as we observed that only TLR3 
ligand poly I:C stimulation induced robust CXCL13 production. 
Although it is unlikely that HBV replicates in KC, activation of 
KC by HBV, and its proteins has been demonstrated. Hösel et al. 
(28) showed that HBV particles and HBsAg induce IL-1β, IL-6, 
CXCL8, and TNF-α production in human KC via NF-κB activa-
tion. Boltjes et  al. (29) demonstrated that a direct interaction 
between HBsAg and KC resulted in HBsAg uptake, induction of 
cytokine production, and the induction of IFN-γ production by 
NK cells. Alternatively, phagocytosis of HBV itself or -infected 
hepatocytes by KC may allow intracellular TLR3 exposure to 
viral RNA (30, 31).
Additionally, CXCL13 expression in KC may be induced by 
the ongoing hepatic inflammation, which maintains the patho-
logic process in the tissue by attracting additional lymphocytes 
and leading to chronic damage. Under chronic HBV infection, 
serum CXCL13 levels were found to be elevated in CHB patients 
compared with HCs. The highest levels occurred in immune-
active patients. It can be interpreted that the high serum levels 
of CXCL13 may be a consequence of high local production. In 
our study, CXCL13 was highly expressed in the ectopic GC of 
CHB liver, co-localized with KC, Tfh cells, and B cells, indicat-
ing that KC-expressed CXCL13 served as a critical regulator 
for the recruitment of CXCR5+ lymphocytes in CHB patients. 
Previously, the immunohistochemical findings in liver biopsies 
suggested a major role for B-cells in the pathogenesis of CHB, 
which appeared to be driven by increased CD20+ B-cells (32). 
In addition, we also completed a comprehensive gene-chip 
analysis of intrahepatic gene expression in patients at differ-
ent phases of HBV infection. Consistently, CHB patients had 
significantly elevated expression of CXCL13 in liver tissues 
compared to the IT and IC groups (data not shown). However, 
no direct correlation between CXCL13 serum levels and ALT 
was detected in our study. Although these findings may indicate 
a lack of a direct effect of CXCL13 on liver inflammation, they 
do highlight the in situ relation between CXCL13 and CXCR5+ 
lymphocytes.
The role of CXCL13 expression has already investigated in 
other types of chronic hepatitis (15, 16). Our group reported 
before that the levels of serum CXCL13 were significantly 
higher in primary biliary cirrhosis patients compared to 
HC. And there was a significantly higher mRNA expression 
of intrahepatic CXCL13 relative to HC and it suggested that 
CXCL13 promoted intrahepatic CXCR5+ lymphocyte hom-
ing and aberrant B  cell immune responses in PBC (15). We 
also compared the serum CXCL13 levels and liver CXCL13 
expression in PBC and CHB patients. It was noted that the 
levels of serum CXCL13 were significantly higher in PBC than 
CHB. In situ staining revealed significantly higher expression 
of CXCL13 within the portal tracts in PBC than CHB (Figures 
FigUre 5 | cXcl13-mediated chemotaxis effect on cXcr5+ cells in vitro. (a) Schematic diagram of chemotaxis assay. A 1 × 106 fresh-isolated peripheral 
blood mononuclear cells were added into the upper chamber, and different concentration of rh-CXCL13 or median alone was added into lower chamber. After 
2–6 h, the cells in the lower chamber were harvested and analyzed. (B) Comparison of the numbers of CXCR5+ cell counting in chronic hepatitis B (CHB) patients 
with different CXCL13 concentration in Transwell assay. Data are representative with mean ± SEM, and determined by Mann–Whitney U test. (c) Comparison of the 
numbers of CXCR5+ cell counting in CHB patients with different incubation time in Transwell assay. Data are representative with mean ± SEM, and determined by 
paired Student’s t-test.
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S3A,B in Supplementary Material). Additionally, serum 
CXCL13 levels were found to be elevated in chronic hepatitis C 
virus infection compared with HC and expression of CXCL13 
protein was evident in inflammatory cells within portal tracts 
and strongly correlated with CD20+ B-cell numbers (16, 33). 
Thus, further studies are necessary to focus and identify the 
relationships and contributions of CXCL13 to patients with 
chronic hepatitis at different stages of inflammatory index of 
liver histology.
To establish whether CXCL13 changes contributed to the 
success of antiviral therapy, serum levels of this chemokine 
were monitored serially throughout the course of telbivudine 
treatment. CXCL13 levels did not change after CR to antiviral 
therapy. On the contrary, CXCL13 significantly declined in NCR 
group during the treatment. ROC curves of the serum CXCL13 
concentrations at 12  weeks were generated to predict a CR at 
52 weeks, but the sensitivity and specificity for detection of a CR 
were not as satisfactory as HBV-DNA levels. Of note, a negative 
correlation between CXCL13 serum levels and circulating viral 
load was noted. Although the combination of weeks 0–12, HBV-
DNA level and serum CXCL13 concentration showed an optimal 
index to predict the CR, the predication value of the ROC curve 
may hard to be applied for clinical guidance due to the limited 
sample size of the patients in this study. In addition, as CXCL13 
expression might be induced by the ongoing hepatic inflamma-
tion, the amelioration of liver inflammation with normalization 
of ALT levels explanted the decrease of CXCL13 expression dur-
ing therapy. However, the higher level of CXCL13 in CR group 
referred to the activation of local anti-HBV immune response to 
contribute to viral control. Related results in our group showed 
the similar tendency of these immune factors during the antiviral 
treatment (17, 19). It was showed serum IL-21 concentration and 
the frequency of circulating Tfh cells were significantly higher in 
CR group compared with NCR group. The significant difference 
between CR and NCR was observed at treatment 12 weeks, the 
time when an increase in the IL-21-secreting Tfh cells that are 
associated with HBeAg seroconversion can be detected (17, 19). 
It could be assumed that Tfh cells and B cells would be attracted 
by CXCL13 and migrate to the liver, where the Tfh cells would 
secrete IL-21 and promote B cell maturation and production of 
antibodies.
In conclusion, we have observed that patients with chronic 
HBV infection have increased serum levels of CXCL13, pos-
sibly as the result of augmented production in the liver by 
FigUre 6 | In situ expression of cXcl13 in the ectopic germinal center (gc) of liver tissue from chronic hepatitis B (chB) patients. (a) 
Immunohistochemical staining of CXCL13 expression in liver tissue samples with or without ectopic GC from CHB patients and healthy control (HC). Representative 
slides were shown with different magnifications as indicated. (B) Immunohistochemical staining of CXCL13+, CD4+, CD19+, CXCR5+, CD38+, and CD68+ cells in 
serial sections of liver tissue samples with ectopic GC from four representative CHB patients. Co-localization of CXCL13 expression was observed with CD68+ KCs, 
CXCR5+ CD4+ T cells, and CXCR5+CD19+ B cells in the ectopic GC (magnification ×400, plotting scale equal to 50 μm).
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KC. In CHB patients, CXCL13 contributes to lymphocyte 
migration to the liver by creating local microenvironments 
supportive of focal B-cell aggregations that have structural fea-
tures remarkably similar to ectopic lymphoid follicles. Higher 
CXCL13 production seems to be involved in viral control 
during antiviral treatment, which suggests the possible use of 
serum CXCL13 monitoring to follow the treatment response 
to antiviral therapy and the prognosis. Future studies are 
also needed to determine whether TLR agonists that activate 
CXCL13 expression represent potential therapeutic agents for 
HBV infections.
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